Fig. 7: ITF2357 reduces tumor growth and potentiates Doxorubicin effect in vivo. | Oncogenesis

Fig. 7: ITF2357 reduces tumor growth and potentiates Doxorubicin effect in vivo.

From: Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma

Fig. 7: ITF2357 reduces tumor growth and potentiates Doxorubicin effect in vivo.

a In vivo response of SW982 xenograft to vehicle (daily), Doxorubicin (Doxo, 2.2 mg/kg per week) or ITF2357 (100 mg/kg per day for 4 days) alone, or in combination (weekly Doxo followed by daily ITF2357 for 4 days). Treatments lasted 4 weeks. b Representative images of immunohistochemical detection of apoptosis by TUNEL assay of tumor xenografts treated as reported in a

Back to article page